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The development of reactions that facilitate a concise path to chemical complexity has long been 
a focus within the synthetic community. Specifically, the use of readily available starting 
materials towards efficient routes to chemically relevant molecules is imperative. These designed 
reactions exhibit utility to applications within synthetic, medicinal, and materials science. 
Herein, efforts to endow the scientific community with efficacious syntheses is realized with the 
step economical synthesis of Vildagliptin.  
A novel Selectfluor-modified palladium catalyst enabled the dehydration of primary amides for a 
concise route to nitrile moieties. These reactions were studied for their unique reactivities and to 
elucidate mechanistic insight. Following successful manipulation of more than 20 substrates, the 
utility of the methodology turned to the total synthesis of Vildagliptin. Vildagliptin is a nitrile 
bearing anti-diabetic medication that can be formed using a primary amide precursor. Once 
Vildagliptin was synthesized using the dehydration methodology, a more efficacious route was 
desired and efforts began towards a one-pot synthesis of the medication. The capability to 
produce chemically relevant products in a step economical manner will benefit not only the 
synthetic community, but also the recipients of medications and products resulting from such 
developments.
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CHAPTER I: INTRODUCTION  
Justification of Synthetic Achievements 
Prevailing universal challenges involve two common themes: elucidating the elemental 
properties of our universe and extending the longevity of our existence. In response to these 
enigmatic quandaries, indelible synthetic achievements have contributed generously to our 
chemical coffers.  As a cornerstone of chemistry, organic synthetic research continues to resolve 
the most fundamental questions about molecular interaction. These answers yield extensions to 
life via development of synthetic medications and comprehensive knowledge about molecular 
interaction.  
The utility of synthetic chemistry hinges on time and step economic realization of more complex 
molecules.1  With this in mind, this thesis presents the use of readily available starting materials 
to yield Vildagliptin (1), an anti-hyperglycemic medication bearing a nitrile moiety (Figure 
1.1).2  
 
Figure 1.1: Vildagliptin, Prolinamide 
This process involves a 1-step in situ synthesis of Vildagliptin beginning with L-prolinamide (2), 
an abundant and easily acquired molecular building block (Figure 1.1).3 L-prolinamide was 
acetylated, coupled with an adamantal moiety, and consequently dehydrated to form 
Vildagliptin. This approach was carried out in a one flask reaction utilizing in situ additions of 
components with a single purification step
 1
Introduction to Nitriles 
The importance of nitriles has significant historical precedence beginning in 1782 with C. W. 
Scheele’s successful preparation of hydrogen cyanide.4 Following a semi-centennial period, 
Wöhler and Liebig reported the first known synthesis of nitriles in 1832 producing benzyl 
cyanide and benzonitrile. However, it was not until 1844 that Hermann Fehling was able to 
characterize benzonitrile by comparison to the known synthesis of hydrogen cyanide.5 Fehling 
conceived the term “nitrile” that is now used to identify the ubiquitous compound.6 Since 
inception, nitriles have expanded into a myriad of applications including more than 30 nitrile 
containing pharmaceuticals currently prescribed.7 Vildagliptin (1) is an antidiabetic medication 
that inhibits dipeptidyl peptidase-IV. Nitrile-containing fluoroquinolones (Figure 1.2, 3) have 
exhibited potency against Methicillin-Resistant Staphylococcus aureus,8 a bacterium attributed 
with high mortality rates,9 and Anastrazole (Figure 1.2, 4) treats osterogen-dependent breast 
cancer.  Materials science uses nitriles to develop designer magnets10 and high-performance 
thermoplastic polymers.11 Perhaps most significant is the organocatalytic manipulation of nitriles 















Nitrile Bearing Fluoroquinolone (3) Anastrazole (4)  
Figure 1.2: Nitrile Containing Pharmaceuticals 
Synthetic methods for nitrile formation command further investigation to meet the diverse 
applications of the functional group.17 New reaction designs may consider transition metal 
complexes. For example, typically PdII catalysts are used to hydrolyze nitriles to amides, but in 
2005 Maffioli18 reported a dehydration of primary amides to nitriles using a PdCl2 catalyst in 
aqueous acetonitrile. In 2018 Croatt et al attempted to semi-synthetically improve the activity of 
 2
Alamethicin F50 (Figure 1.3) by fluorination using Selectfluor and Pd(OAc)2, and inadvertently 
developed a novel dehydration methodology to produce nitriles.19 Application of this synthetic 
methodology to the formation of molecules such as Vildagliptin 1 can mitigate issues inherent to 
nitrile installation in the presence of other functional groups.20 
 
Figure 1.3: Alamethicin F50 and Dehydrated Alamethicin F50 
Discovery of Vildagliptin 
In 1991 Novartis® began the grassroots efforts into the application of dipeptidyl peptidase IV 
inhibitors. Eventually this work led to the discovery of Vildagliptin (1) as an antidiabetic agent in 
1998.21 Vildagliptin is an aminonitrile containing drug for monotherapy or used in combination 
with Metformin, another type-2 diabetic medication.22 Vildagliptin has less undesired side 
effects than Metformin, although slightly less effective, and functions by inhibiting dipeptidyl 
peptidase IV (DPP IV). The DPP IV enzyme rapidly metabolizes incretins,23 and inhibiting the 
protein extends the action of incretins which increase pancreas activity for secretion of insulin, 
thus functioning as an antihyperglycemic treatment for type-2 diabetes. As one of the most 
chronic diseases in the world, type-2 diabetes requires more efficacious synthetic routes to drugs 
like Vildagliptin.24  
Although initial syntheses of Vildagliptin remain patent protected, a 2003 publication by E.B. 
Villhauer25  reports a 3-step synthesis in which L-prolinamide (2) is first acetylated (Figure 1.4), 
and then dehydrated to yield the nitrile (8) from its respective amide (7). The resulting (S)-1-(2-
 3
chloroacetyl)pyrrolidine-2-carbonitrile (8) is then coupled to 3-amino-1-adamantanol (9) to yield 
Vildagliptin (1) in 14-23% yield.  
 
Figure 1.4: Villhauer Approach to Vildagliptin 
Pharmaceutical interest in Vildagliptin encouraged other synthetic routes including a 3-step 
synthesis in 2013 from Glenmark employing Vilsmeier’s reagent, gold, and SOCl2.26 In 2014,  
Deng used L-proline starting material in a 4-step synthesis that improved typical yields to 59%.27 
Notably, Deng employed Finkelstein conditions when adding the adamantal moiety to promote 
decreased reaction times.28 In 2015, Novartis adapted the Vildagliptin synthesis to flow 
chemistry reactors to streamline the production and maintained a 3-step synthetic route.29 
Adapting reaction conditions to continuous flow and batch technologies implements safer 
practices for industrial environments and prevents time lost to isolation of materials over 
multiple steps. In context of this advantage, the authors determined isolation of (S)-1-(2-
chloroacetyl)pyrrolidine-2-carbonitrile (8) was essential prior to attaching the adamantal moiety. 
This is a significant impediment to the flow chemistry process, and formation of the nitrile 
intermediate continues to be a point of contention in the full synthesis of Vildagliptin.  
Seeking to resolve synthetic obstacles to Vildagliptin, the Croatt group has developed a synthetic 
strategy to potentially afford Vildagliptin in a single pot.  Converting L-prolinamide to 
Vildagliptin in a single pot has attractive complexity in both industrial and academic fields. Use 
 4
of the Croatt group’s previously developed dehydration conditions provides the ability to 
rearrange the synthetic pathway and mitigate complications with formation or isolation of nitrile 
intermediate 8. Also important is the ability to dehydrate natural products to cyano-bearing 
structural analogs. Nitrile-containing enzymes are studied for synthetic applications30 and more 
than 120 nitrile-containing natural products are currently known.31 Understanding the influence 
of nitrile-containing natural products on the bacterial community is an urgent target,32 and a 
synthetic method for nitrile installation can facilitate elucidation of their biological role.33 
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CHAPTER II: DEVELOPMENT AND UTILIZATION OF A PALLADIUM CATALYZED 
DEHYDRATION OF PRIMARY AMIDES TO FORM NITRILES 
This article was published in the Journal of Organic Chemistry and is presented as published. My 
personal contributions to this manuscript include optimization of the dehydration conditions, 
synthesis of primary amides, subsequent dehydrations, qualitative and quantitative analysis. I 
also contributed to the writing of the manuscript, including development of the supporting 
information. 
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Abstract 
 A palladium(II) catalyst, in the presence of Selectfluor, enables the efficient and chemoselective 
transformation of primary amides into nitriles. The amides could be attached to aromatic rings, 
heteroaromatic rings, or aliphatic side chains, and the reactions tolerated steric bulk and 
electronic modification. Dehydration of a peptaibol containing three glutamine groups afforded
 6
 structure-activity relationships for each glutamine residue. Thus, this dehydration can act 
similarly to an alanine scan for glutamines via synthetic mutation.  
In the area of new reaction design and development, the chemoselective interconversion of 
functional groups is highly sought after.34 Two noteworthy examples include 1) the selective 
methylation of the carboxylic acid of amphotericin B in the presence of seven alkenes, nine 
secondary alcohols, a hemiacetal, and a primary amine35 and 2) the C-H oxygenation of a 
bryostatin analogue with DMDO in the presence of eleven similar C-H bonds, an alkene, an 
acetal, and three carboxyl groups.36 The first case represents the conversion of a carboxylic acid 
to an ester, a relatively simple transformation that modifies reactivity, but the conversion in 
amphotericin B is complicated by the other functional groups surrounding it.  For example, 
typical Fisher esterification using strong acid is not compatible with this molecule.  Similarly, the 
dehydration of a primary amide to form a nitrile, which has been previously explored,18 is often 
complicated by the presence of other functional groups.24  Transition metal catalyzed 
dehydration reactions typically utilize acetonitrile18,37 or N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA)38,39,40 as a  dehydrating agent (Scheme 2.1). These 
reactions generate acetamide as a byproduct from acetonitrile or N-methyltrifluoroacetamide and 
hexamethyldisiloxane from MSTFA. For reactions involving MSTFA, high reaction 
temperatures and excess amounts of MSTFA are required. Non-aqueous acetonitrile reactions 
require excess amounts of lithium and silver salts.37 On the other hand, reactions involving water 
as co-solvent can proceed at room temperature,18 but are limited to substrates that are stable and 
soluble under aqueous conditions (Scheme 2.1, a) 
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Scheme 2.1: Methods to Convert Primary Amides to Nitriles 
During our studies to semi-synthetically improve the activity of natural products, typically by 
incorporating fluorine into the molecule,41 we attempted to fluorinate alamethicin F50, a 20-mer 
peptaibol containing an acetylated N-terminus, a C-terminal phenylalaninol, and three glutamine 
(Gln) residues (Gln7, Gln18-19; Scheme 2.2).42  Although our fluorination attempts were 
unsuccessful,43 it was determined that all three glutamine residues were dehydrated in the 
presence of Pd(Oac)2 and Selectfluor. This led to the formation of tricyano product 2, along with 
semi-dehydrated analogues (3-8; vide infra).  This transformation was efficient and completely 
chemoselective without modifying the primary alcohol or any of the secondary or tertiary 
amides.  Herein, we describe the further optimization and exploration of this dehydration 
reaction and utilize the dehydration of alamethicin F50 to illustrate the benefits of this reaction as 




Scheme 2.2: Identification of a Chemoselective Dehydration 
To examine the optimal conditions of the dehydration of primary amides, 4-methoxybenzamide 
was used as a model substrate in the presence of catalytic amounts of various metal salts and 
Selectfluor. The reaction gave excellent yields of the nitrile product in the presence of Pd(II) or 
Pd(0); contrasting results were observed with Zn(II) or Cu(II) catalyzed reactions (Table 2.1, 
entries 1-5). Although the Pd2(dba)3 reaction appears faster than that with Pd(Oac)2, the 
purification was complicated by the dba (dibenzylideneacetone) ligand. Thus, catalyst loading 
and Selectfluor stoichiometry were examined using the Pd(Oac)2 catalyst.  Using 5 mol  % of 
catalyst, the reaction yielded 71% of the desired nitrile after 16 h (Table 2.1, entry 6). Increasing 
the amount of Selectfluor to 40% gave nitrile 10a, in addition to the fluorinated nitrile derivative 
(Table 2.1, entry 8). Reactions performed in the absence of Selectfluor or in the presence of 
DABCO instead of Selectfluor yielded no nitrile product. Although Selectfluor is a non-
hygroscopic reagent, we examined the requirement for water using Pd(Oac)2 in the absence of 
Selectfluor (Table 2.1, entries 11-13). Increasing the amount of water in the reaction improved 
the reaction yield (68% was observed with 2.0 equiv of water). For comparison, the addition of 
water to the reaction conditions with Selectfluor was not beneficial.  A previous report by 
Maffioli18 found that the palladium-catalyzed dehydration requires water. We verified their 
results in the absence of Selectfluor, which indicates that Selectfluor is modifying the catalytic 
 9
cycle,37 such that water is no longer required.  After screening a variety of conditions, the 
optimal conditions were determined to be using 10 mol % Pd(Oac)2 and 20 mol % Selectfluor in 
acetonitrile (entry 1) 
Table 2.1: Optimization of Palladium-Catalyzed Dehydration with Selectfluor 
 
 
entry cat. (mol %) additive (mol %) time (h) yield (%)a  
1 Pd(Oac)2 (10) Selectfluor (20) 16  96 
2 PdCl2 (10) Selectfluor (20)  16  82 
3 Pd2(dba)3 (5) Selectfluor (20) 13  91 
4 ZnBr2 (10) Selectfluor (20) 24  trace 
5 Cu(Otf)2 (10) Selectfluor (20) 24  26 
6 Pd(Oac)2 (5) Selectfluor (20)  16  71 
7 Pd(Oac)2 (10) -- 24  trace 
8 Pd(Oac)2 (10)  Selectfluor (40) 16  93b 
9 Pd(Oac)2 (10) Selectfluor (5) 24  88 
10 Pd(Oac)2 (10)  DABCO (20)  24  NRc 
11 Pd(Oac)2 (10) H2O (50)  16  31 
12 Pd(Oac)2 (10) H2O (100) 16  42 
13 Pd(Oac)2 (10) H2O (200) 16  68 
[a] Isolated yield. [b] 7% Fluorinated 4-methoxybenzonitrile was observed. [c] No reaction. 
 
With the optimal conditions in hand, a series of primary amides were synthesized from their 
respective carboxylic acids and screened in the dehydration conditions (Scheme 2.3).  The 
substrate scope is broad, with high yields for both aliphatic and aryl amides to generate aliphatic 
and aryl nitriles. High yields were observed from reactions involving non-, mono-, and di-
substituted benzamides (10a-c and 10e-g; 80-96% yields). The lower yield for compound 10d (4-
trifluoromethylbenzamide, 42% yield) was likely due to electronic factors. However, the effect 
was negligible on cinnamide derivatives (10h-10j). Several aliphatic amides were also converted 
to their corresponding primary, secondary, and tertiary nitriles in good yields. Importantly, the 
cyclopropyl moiety in amides (9t-9v) has been preserved under the reaction conditions to 
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generate cyclopropyl nitriles (10t-10v) in excellent yields (86-93%).  In total, 22 substrates were 
screened, and it was determined that this reaction tolerates the presence of alkenes, aromatic 
rings, heteroaromatic rings, nitro groups, cyclopropanes, and halides. To further test the 
chemoselectivity of the reaction, we ran the dehydration of 9a in the presence of either 
salicylaldehyde or 4-phenylbutyric acid. These reactions gave desired product 10a (93% and 
95% yield, respectively) with a quantitative recovery of salicylaldehyde and 4-phenylbutyric 
acid, illustrating that phenols, aldehydes, and carboxylic acids are also tolerated. 
Based on our results and the similarity of conditions to prior reports,18 the reaction mechanism 
(Scheme 2.4) might involve the formation of a mixed imidic anhydride (B) that undergoes proton 
transfer and coordination of acetate (C) followed by an elimination to yield the desired nitrile 
and acetamide (D), as has been proposed previously.37 The role of  Selectfluor remains uncertain, 
but one potential option is that it accelerates the catalytic cycle by formation of a Pd(IV) catalyst, 
as has been reported by others.43,44 Additional evidence in support of a Pd(IV) mechanism is the 
observation of a signal at -181 ppm in the 19F NMR when Pd(Oac)2 is added to Selectfluor (19F 
NMR signals for SelectFluor are 48 (N-F) and -151 (BF4) ppm, Supporting Information (SI)).  A 








Scheme 2.4: Postulated Mechanism for Dehydration 
To further establish the utility of the dehydration, alamethicin F50 was re-examined as a starting 
material (1; Scheme 2.5), with an approach focused on the exploration of the structure-activity 
relationship of the different primary amides. The reaction of compound 1 with SelectFluor (1.0 
equiv) and Pd(Oac)2 (5 mol %) in MeCN (0.1 M) at room temperature for 12 h gave the tricyano 
peptaibol derivative (2; 47% yield after purification), along with the dicyano product (3) where 
the glutamines at positions 18 and 19 were dehydrated (13% yield after purification). The 
structures of compounds 2 and 3 were confirmed by 1H and 13C NMR spectroscopy and 
HRESIMS/MS data (SI).  
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Pd(OAc)2 (5 mol %)
Selectfluor (1 equiv)
MeCN (0.1 M), rt, 12 h
2 (47%); 3 (13%)
or
Pd(OAc)2 (5 mol %)
Selectfluor (1 equiv)
MeCN (0.1 M), rt
90 min (Figure 1)
R, R', R'' = CONH2; Alamethicin F50 (1)
R, R', R'' = CN; (2)
R = CONH2, R' = R'' = CN (3)
R' = CONH2, R = R'' = CN (4)
R'' = CONH2, R = R' = CN (5)
R = R' = CONH2, R'' = CN (6)
R = R'' = CONH2, R' = CN (7)





























































Scheme 2.5: Synthesis of mono-, di- and tri-cyano alamethecin F50 analogues 
Scaling up of the reaction with SelectFluor in acetonitrile permitted the isolation, structural 
characterization, and biological evaluation of dehydrated analogues 2-8.  The structures of these 
analogues were established through analyses of their HRESIMS/MS spectra (SI). Importantly, 
these seven analogues were all accessed by a single reaction using 1 as the starting material 
instead of designing and developing seven different approaches or through the use of protecting 
groups.45 Furthermore, in contrast to the more typically used alanine scan,46 this method has a 
minimal change in the overall sterics of the sidechain since there is no deletion of carbon over 







Figure 2.1: HRESIMS spectra of the reaction of 1 (10 mg, 5.9 µmol) with SelectFluor (2.1 mg, 
5.9 µmol) and Pd(Oac)2 (0.011 mg, 0.05 µmol) in MeCN (0.1M) at 25 °C after 90 
min. In black is the base peak chromatogram, in maroon the extracted ion 
chromatogram for the staring material (1) at m/z 1963.0, in green the extracted 
ion chromatogram at m/z 1945.0 for the monocyano products (6-8), in navy the 
extracted ion chromatogram at m/z 1927.0 for the dicyano products (3-5), and in 
yellow the extracted ion chromatogram at m/z 1909.0 for the tricyano product (2). 
Alamethicin F50 (1) is known to be antibacterial, antifungal, anthelmintic, and cytotoxic.42,47 
Based on our groups’ attempts to generate anticancer leads,41,48,49 we decided to determine the 
impact of the glutamine residues on the bioactivity in a panel of cancer cell lines (Table 2.2). The 
cytotoxicity data indicated that the glutamine at position seven was crucial for maintaining the 
cytotoxic properties of the molecule. This was determined since the analogue dehydrated 
exclusively at position seven (8) was inactive, whereas monocyano 6 and 7 were active.  
Similarly, dicyano 5 and 4, both of which had position seven dehydrated, were inactive or much 
less active, respectively.  Dehydration of glutamine 18 and/or 19 led to analogues that had 
similar activities. These results give unique insight into the impact of each glutamine residue on 






Table 2.2: Cytotoxicity of Alamethicin F50 and Dehydrated Analogues 
compound MDA-MB-435 MDA-MB-231 OVCAR3 
1 4.4 3.7 7.8 
2; R,R’,R’’ = CN >25 >25.0 >25 
3; R’,R’’ = CN 2.6 1.2 3.0 
4; R,R’’ = CN 3.1 8.7 13.4 
5; R,R’ = CN >25 22.3 >25 
6; R’’ = CN 2.2 1.3 4.6 
7; R’ = CN 2.8 2.0 3.9 
8; R = CN >25 >25 >25 
Taxol 0.0005 0.009 0.002 
[a] IC50 values in the indicated cell lines were determined as the concentration 
required to reduce cellular proliferation by 50% relative to the untreated controls 
following 72 h of continuous exposure. 
 
Several techniques, including X-ray diffraction,50 NMR,42,51,52 CD,53 Raman, and molecular 
dynamics,42,54 have been used to characterize the α-helical conformation of alamethicin F50 (1) 
in both solution and solid states.42 In an attempt to gain information about the conformational 
changes induced by the dehydration of the glutamine residues in 1, the CD spectrum for each 
analogue was recorded in MeCN (Figure 2.2). The far UV/CD spectra, 260-180 nm, with 
absorbances attributed to the peptide bond, is the most extensively used spectroscopic readout to 
determine the secondary structures of peptides in solution (α-helix, β-pleated sheet, and random 
coil).55 The right handed α-helix is reported to give two negative Cotton effects at 222 and 208 
nm, while the β-pleated sheet shows one negative and one positive Cotton effect at 217 nm and 
198 nm, respectively.55 
Analysis of the experimental CD data obtained for alamethicin F50 (1) and its analogues (2-8) 
indicated that the mono- and dicyano compounds (3-8) predominantly retained the α-helical 
conformation, with a minor population of 310-helix, as previously reported by Peggion et al.56 
However, the CD spectrum for tricyano 2 indicated that the conformation was modified, 
increasing the population of the 310-helix conformer (Figure 2.2 and SI). Surprisingly, the helical 
nature of the different peptaibol analogues did not have a strong correlation with the cytotoxicity 
data (compare Figure 2.2 and Table 2.2).  In Figure 2.2, the UV/CD spectra of alamethicin F50 
(1) is most similar to that of monocyano analogues 6-8, but analogue 8 is inactive.  Likewise, 
there is a grouping in the spectra of dicyano analogues 3-5, but analogue 3 is active, whereas 
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analogue 5 is inactive and compound 4 has decreased activity.  These data indicate that the 
cytotoxicity of alamethicin F50 is dependent on the presence of a glutamine residue at position 
seven, and that the activity is not simply a stabilization of the α-helix conformation of the 
peptaibol 
 
Figure 2.2: Far UV/CD-spectra for alamethicin F50 (1) and its dehydrated analogues (2-8). 
In summary, a Selectfluor-modified palladium catalyst was shown to enable the chemoselective 
dehydration of primary amides to generate nitriles. The reaction tolerates the presence of primary 
alcohols, primary amides, secondary amides, aldehydes, carboxylic acids, nitro groups, alkenes, 
heteroaromatic rings, halides, and cyclopropanes and is efficient with aromatic and aliphatic 
amides, with little impact by the electronics or sterics of the system. The application of the 
dehydration method facilitated the synthesis of the seven possible dehydrated analogues of 
alamethicin F50 (1). Importantly, all the peptaibol derivatives were generated in a single reaction 
in sufficient amounts for purification, characterization, and biological evaluation. The 
application of this methodology allowed us to generate data that highlight the importance of each 
individual glutamine residue on the bioactivity and conformation of 1. We hypothesize that this 
primary amide dehydration methodology may be used as an alternative to alanine scanning to 
assess the implications of glutamine and possibly asparagine residues in the activity and 3D 






Experimental information and spectral data for all compounds and cytotoxicity data for 
compounds 1-8 
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CHAPTER III: SYNTHESIS OF VILDAGLIPTIN AND APPLICATION OF DEHYDRATION 
METHODOLOGY 
Probing the Synthetic Route to Vildagliptin 
Tandem reactions were used for the synthesis of Vildagliptin from commercially available 
starting materials in one step, which is at least two fewer steps compared to previously reported 
syntheses (Scheme 3.1).25 The synthesis described herein rearranges a traditional pathway to 
Vildagliptin resulting in a final dehydration step. 
 
Scheme 3.1: Villhauer Approach to Vildagliptin 
The route in Scheme 3.2 begins with the acetylation of L-prolinamide (2) using K2CO3 as a base 
and acetonitrile as a solvent.57 After stirring under N2 atmosphere at 30 °C for 15 hours the 
acetylated L-prolinamide (7) is afforded. In the same pot, 3-amino-1-adamantanol (2 eq), NaI (2 
eq), and K2CO3 (2 eq) are added with CH3CN (0.9 M). Introducing Finkelstein conditions 
promotes the formation of iodinated intermediate 10 yielding N-(3-hydroxy-1-
adamantanol)glycyl-L-prolinamide (11) after stirring under N2 at 35 °C for 15 hours. In the same 
pot the crude mixture is then subjected to dehydration conditions using Pd(OAc)2 (10 mol %) 
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and Selectfluor (20 mol %) with aqueous CH3CN as the solvent.  After stirring under N2 at room 

























Pd(OAc)2 10 mol %
Selectfluor 20 mol %
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Scheme 3.2: One-pot Synthesis of Vildagliptin 
Variations of the synthetic path to Vildagliptin were probed prior to realizing the one-pot route in 
Scheme 3.2. Efforts to acetylate L-prolinamide were initially facilitated with Et3N (2 eq), DMAP 
(1 mol %), and DMF (Scheme 3.3). Problematic purification (removal of DMF), lengthy reaction 
times, and low yields resulted in divergent conditions with K2CO3 as base and CH3CN for 
solvent as seen in Scheme 3.2 
 
Scheme 3.3: Preliminary Conditions for Acylation of L-prolinamide 
Also investigated was the dehydration of L-prolinamide using Pd(OAc)2 (10 mol %) and 
Selectfluor (13) (20 mol %) with CH3CN as solvent (Scheme 3.4). The unsuccessful dehydration 
(A) led to an investigation (B) that determined Selectfluor was oxidizing the amine of L-
prolinamide to yield 3,4-dihydro-2H-pyrrole-5-carboxamide (12). 
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Scheme 3.4: Dehydration of L-prolinamide 
In an alternate pathway, 1-chloroacetyl-2-(S)-pyrrolidinecarboxamide (7) was isolated and 
subsequently dehydrated to yield (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile (8) (Scheme 
3.5) prior to installing the adamantal moiety to yield Vildagliptin (1). When converting the amide 
product 7 to the nitrile derivative 8 the oxidation of the amine is less favored due to the reactivity 















Pd(OAc)2 10 mol %
Selectfluor 20 mol %

















Scheme 3.5: Initial Route to Vildagliptin 
Although the synthetic route exhibited in Scheme 3.5 was viable, the desire for enhanced 
chemical complexity in fewer steps remained a focal point for the synthesis of Vildagliptin. 
Consequently, a one-component solvent system was investigated for single-pot compatibility. 
Due to its required use for dehydration of 7 to its respective nitrile (8), acetonitrile was deemed a 
suitable solvent for tandem in situ reactions. To probe this, the solvent used for acylation of L-
prolinamide in Scheme 3.5 (CHCl3) was substituted with acetonitrile. Upon actualization, 1-
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chloroacetyl-2-(S)-pyrrolidinecarboxamide (7) was subsequently reacted with 3-amino-1-
adamantanol (9) in situ to yield N-(3-hydroxy-1-adamantanol)glycyl-L-prolinamide (11) 
(Scheme 3.2). These results indicated acetonitrile as a workable solvent as well as the ability to 
install an adamantal moiety prior to dehydration of 7. With this knowledge in hand Scheme 3.2 
was developed. 
Challenges to Dehydration 
Inaugural efforts to convert the primary amide of N-(3-hydroxy-1-adamantanol)glycyl-L-
prolinamide (11) to a nitrile did not yield target molecule 1 by NMR analysis. The reaction 
utilized unpurified starting material in accordance with in situ conditions. To this crude solution 
Pd(OAc)2 (20.9 mg, 0.093 mmol, 10 mol %) was added and the solution assumed a light brown 
color. Subsequently Selectfluor was added (67 mg, 0.19 mmol, 20 mol %). Upon addition of 
Selectfluor the reaction exhibited an intense color change from light brown to a dark red-orange. 
Similar color changes were observed from the oxidation of L-prolinamide in Scheme 3.4. 
Considering the possibility of oxidation at the secondary amine of 11, a control experiment was 
performed without Pd(OAc)2 (Scheme 3.6 B). This reaction returned the same results in the 
absence of Pd(OAc)2, indicating the Pd was likely not entering the catalytic cycle, and 
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Scheme 3.6: Probing the Dehydration Reaction 
 
This knowledge is valuable to the developed dehydration methodology19, and indicates 
limitations for substrates possessing secondary amines. To mitigate the Selectfluor promoted 
oxidation of N-(3-hydroxy-1-adamantanol)glycyl-L-prolinamide 11, efforts were made to stir 
Pd(OAc)2 with Selectfluor prior to addition to the reaction mixture. In a 4 mL vial Pd(OAc)2 (10 
mol %) and Selectfluor (20 mol %) were combined and stirred in CH3CN (10 minutes) before 
injecting the catalytic mixture into the reaction vessel. Ostensibly, the Selectfluor would promote 
a higher oxidation state of Pd(OAc)2, which would in turn react with the substrate 11. 
Unfortunately, similar results to Scheme 3.6 were obtained and none of the target molecule was 
recovered.  
After discerning the oxidative relationship between Selectfluor and 11, it was decided to 
interrogate the impact of the crude in situ mixture on Pd(OAc)2. In order to do this N-(3-
hydroxy-1-adamantanol)glycyl-L-prolinamide (11) was synthesized and purified. The 
expectation was to expose pure 11 to the dehydration conditions to determine if the crude 
reaction mixture was indeed hindering the catalytic cycle. The pure N-(3-hydroxy-1-
adamantanol)glycyl-L-prolinamide (50.0 mg, 0.16 mmol, 1 eq) was placed in a 4 mL vial with 1 
mL CH3CN. In a separate 4 mL vial Pd(OAc)2 (180 µL: 20 mg/mL CH3CN, 3.59 mg, 0.016 
mmol, 10 mol %) and Selectfluor (532 µL: 20 mg/mL CH3CN, 10.63 mg, 0.03 mmol, 20 mol %) 
were stirred for 10 minutes, and then injected into the reaction vial. After stirring for 24 hours 
the reaction mixture was heterogenous, and the starting material unconsumed. It was determined 
that isolating N-(3-hydroxy-1-adamantanol)glycyl-L-prolinamide from the crude in situ solution 
results in a compound no longer soluble in CH3CN.  
Due to the time and effort required to synthesize N-(3-hydroxy-1-adamantanol)glycyl-L-
prolinamide, it was decided to use a sample substrate to further investigate the effects of a crude 
in situ mixture on the dehydration methodology. To create a model substrate 3,4-
dimethoxybenzoic acid 14 was used to form 3,4-dimethoxybenzamide 15 (Scheme 3.7) which 
was subsequently probed for in situ compatibility. 
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Scheme 3.7: Synthesis of 3,4-dimethoxybenzonitrile 
As seen in Scheme 3.7 the dehydration of amide 11 to the nitrile bearing Vildagliptin 1 is carried 
out via in situ addition of palladium acetate and Selectfluor. The previous stage of the reaction 
scheme involves the addition of K2CO3 (2 equivalents). Previous syntheses indicate the need for 
isolation of intermediates and removal of K2CO3 prior to realizing 1,29and indicate residual 
carbonate within the reaction mixture may inhibit the final dehydration reaction to yield target 
molecule 1. To investigate this possibility the palladium catalyzed dehydration of 3,4-
dimethoxybenzamide in Scheme 3.12 was performed with the addition of K2CO3 (2 equivalents). 
Previous results for this reaction experienced a 96% yield19, however in the presence of K2CO3 a 
much lower 7% yield was observed. Thus, support for potassium carbonate hindering the 
reaction was revealed. Compelled to thwart this issue, another reaction was conducted to 
determine if the residual salts or carbonate in solution was culpable (Scheme 3.8).  
 
Scheme 3.8: Doped CH3CN Dehydration 
The solvent (CH3CN) was first stirred with K2CO3 for 2 hours before filtering the solids and 
using the “doped” solvent for the dehydration reaction. The product was recovered in 27% yield. 
Literature values for this reaction are very good at ~ 97% yield, indicating that the carbonate in 
the solvent is hindering the reaction mechanism. However, the dramatic increase in yield 
indicates the solids from K2CO3 may also serve an inhibitory role. One hypothesis is K2CO3 
creates a more basic solution where a less oxidized Pd0 species is preferred, as promoted by 
Pourbaix.58This reduced Pd species does not subscribe to the purported catalytic mechanism for 
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the dehydration of primary amides to nitriles19, and may indicate limitations to the substrate 
scope. 
Conclusions and Future Work 
This work sought to achieve a concise synthesis of Vildagliptin, a commercially produced anti-
hyperglycemic medication. The work also focused on developing a one pot in situ synthesis 
through application of a previously developed palladium catalyzed dehydration of primary 
amides to nitriles. The very mild and highly chemoselective nature of the dehydration 
methodology indicates broad utility for various substrates and was conducive to achieving a 
short 3-step synthesis of Vildagliptin. 
Achieving a one-pot in situ synthesis of Vildagliptin is not yet successful due to the nature of 
intermediate products, organization of synthetic steps, and a component-driven catalytic 
inhibition of dehydration. Intermediate nitrile bearing products once isolated became insoluble in 
the solvent system and were not productive to sequential reactions. The developed scheme for 
synthesizing Vildagliptin requires in situ addition of successive materials and a single-
component solvent system. This approach mitigates the solubility issues observed, but presents 
other calamities resulting from K2CO3 used in the one-pot system. Obstruction of the catalytic 
path by K2CO3 shunts the purported relationship between Pd(OAc)2 and Selectfluor in the 
reaction. This in turn promotes the oxidation of the substrate at the secondary amine. 
Discovering this potential oxidation is vital to further applications of the dehydration 
methodology. Dehydrating a substrate scope containing a variety of amines may yield 
clarification. For this work, rearranging the synthetic path to Vildagliptin may present solutions 
to this issue, but after probing a myriad of routes to an in situ synthesis this is likely not practical.  
Future work should include the stoichiometric manipulation of Selectfluor in the reaction to 
determine if excess Selectfluor is effectively oxidizing the substrate. 
In conclusion, readily available starting materials were used to efficiently synthesize Vildagliptin 
in 3-steps by converting an amide intermediate to the nitrile bearing product. The 3-step 
synthesis validates a developed palladium catalyzed dehydration with application for generating 
medications that include nitrile moieties.  Efforts to further consolidate the production to a one-
 25
pot in situ synthesis were not fruitful, but proffered valuable information indicating limits of the 
dehydration methodology with regards to K2CO3 salts and/or secondary amines. 
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CHAPTER IV: EXPERIMENTAL DATA 
General Information 
All anhydrous reactions were performed with dry solvents in oven dried glassware under a 
nitrogen atmosphere.  Unless otherwise noted, all solvents and reagents were obtained from 
commercial sources and used without further purification. Chromatographic purification was 
performed using silica gel (60 Å, 32-63 μm). NMR spectra were recorded using a JEOL ECA 
spectrometer (500 and 400 MHz for 1H, 125 and 100 MHz for 13C). Coupling constants, J, are 
reported in hertz (Hz) and multiplicities are listed as singlet (s), doublet (d), triplet (t), quartet 
(q), doublet of doublets (dd), triplet of triplets (tt), multiplet (m), etc. IR data was obtained with a 
Perkin Elmer FTIR spectrometer with ATR sampling accessory with frequencies reported in cm-
1. High Resolution Mass Spectra were acquired on a ThermoFisher Scientific LTQ Orbitrap XL 
MS system. 
 
Scheme 4.1: Preliminary Acetylation of L-prolinamide25 
L-prolinamide (50.0 mg, 0.44 mmol, 1 eq) was placed into an oven dried 25 mL round bottom 
flask with a magnetic stir bar. The flask was placed into an ice bath before adding 1.0 mL of 
DMF. Ice-chilled chloroacetyl chloride (54.7 mg, 0.48 mmol, 1.1 eq) was slowly added to an 
aliquot of DMF (1.0 mL) in a separate vessel, exhibiting white smoke. This solution was then 
injected dropwise into the reaction flask. Pre-cooled Et3N (90.0 mg, 0.88 mmol, 2 eq at 0 °C) was 
then added dropwise to the reaction flask. Subsequently DMAP (0.54 mg, 0.004 mmol, 1 mol%) 
was added to the reaction flask which was then capped and stirred as the ice bath proceeded to 
room temperature. After stirring for 27 hours the crude mixture was extracted with EtOAc (3 x 
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25 mL). The combined organic layers were washed with H2O (3 x 25 mL) and then once with 
brine (25 mL). The combined organic layers were dried over sodium sulfate and concentrated 
under reduced atmosphere. Product was a tan foam (23.0 mg, 28% yield) with residual DMF 
observed.  
 
Scheme 4.2: General Procedure for Palladium Catalyzed Dehydration (1-chloroacetyl-2-(S)-
pyrrolidinecarboxamide shown).19 
In an oven dried 20 mL vial 1-chloroacetyl-2-(S)-pyrrolidinecarboxamide (20.0 mg, 0.10 mmol, 
1 eq), palladium acetate (0.23 g, 0.01 mmol, 10 mol%), Selectfluor (7.4 mg, 0.02 mmol, 20 mol 
%) and a magnetic stir bar were combined. The dark yellow solution was stirred at room 
temperature for 9 hours before purification on a silica gel column (100 mL 70% EtOAc:Hex). 













24% yield  
Scheme 4.3: Addition of adamantal moiety to (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile25 
In an oven dried 20 mL vial (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile (10 mg, 0.06 mmol, 
1 eq), 3-amino-1-adamantanol (12 mg, 0.07 mmol, 1.2 eq), and K2CO3 (45 mg, 0.32 mmol, 5.5 
eq) were combined in DCM (2.0  mL) with a magnetic stir bar. After stirring for 48 hours the 
salts were filtered from the reaction mixture and rinsed with DCM (5.0 mL). The filtrate was 
concentrated under reduced atmosphere before purification on a silica gel column (Gradient, 
50% MeOH to 100% MeOH). The product, Vildagliptin, was a white solid (4.3 mg, 24% yield).  
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Scheme 4.4: General procedure for Acetylation of L-prolinamide57 
In a 10 mL oven dried vial L-prolinamide (0.1 g, 0.88 mmol, 1 eq), K2CO3 (240 mg, 1.8 mmol, 2 
eq) and a magnetic stir bar were combined in 3.2 mL CH3CN. The vial was placed under N2 
atmosphere and in an oil bath at 30 °C. A solution of chloroacetyl chloride (110 µL in 0.8 mL 
CH3CN, 0.15 g, 1.4 mmol, 1.5 eq) was injected to the reaction flask dropwise over the span of 
1.5 hours. The resulting light-yellow mixture was stirred overnight before filtering the salts, 
drying the filtrate over sodium sulfate, and subsequent concentration under reduced atmosphere. 
The resulting yellow oil was purified on a silica gel column (30 mL 5% CH3CN: EtOAc, 30 mL 
10% CH3CN:EtOAc, 30 mL 100% CH3CN, 50 mL 100% MeOH), yielding a slightly yellow oil. 
The oil was sonicated in CH3CN (0.2 mL) and then concentrated under reduced vacuum. After 
removing the solvent, the oil was placed under high-vacuum to instantly yield a white solid foam 
(90 mg, 54% yield.)  
 
Scheme 4.5: Addition of adamantal moiety to 1-chloroacetyl-2-(S)-pyrrolidinecarboxamide25 
In a 25 mL oven dried vial 1-chloroacetyl-2-(S)-pyrrolidinecarboxamide (0.33 g, 1.8 mmol, 1 
eq), 3-amino-1-adamantanol (0.56 g, 3.5 mmol, 2 eq),  NaI (0.52 g, 3.5 mmol, 2 eq), and K2CO3 
(0.49 g, 3.5 mmol, 2 eq) were combined in CH3CN (18 mL, 0.1 M) with a magnetic stir bar. The 
reaction vial was capped, flushed with N2, and heated in an oil bath (35 °C, overnight). The salts 
were filtered from the reaction mixture and rinsed with CH3CN (10 mL). The filtrate was dried 
over sodium sulfate and concentrated under reduced atmosphere. The resulting yellow oil was 
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purified on a silica gel column (200 mL 50% CH3CN : EtOAc) yielding an off white-yellow 
solid (0.49 g, 87 % yield).  
 
Scheme 4.6: General tandem in situ reactions in one-pot towards Vildagliptin 
In a 25 mL oven dried vial L-prolinamide (0.1 g, 0.9 mmol, 1 eq), K2CO3 (0.24 g, 1.8 mmol, 2 
eq) and a magnetic stir bar were combined in 4.0 mL CH3CN. The vial was placed under N2 
atmosphere and in an oil bath at 30 °C. A solution of chloroacetyl chloride (110 µL in 0.8 mL 
CH3CN, 0.15 g, 1.4 mmol, 1.5 eq) was injected to the reaction flask dropwise over the span of 
1.5 hours. The resulting light-yellow mixture was stirred overnight. Next, 3-amino-1-
adamantanol (0.3 g, 1.8 mmol, 2 eq), and NaI (0.26 g, 1.8 mmol, 2 eq), K2CO3 (0.24 g, 1.8 
mmol, 2 eq), and additional CH3CN (2.0 mL, 0.1 M) were added to the reaction flask. The 
reaction vial was recapped, flushed with N2, and heated in an oil bath (35 °C, overnight). To the 
same pot palladium acetate (21 mg, 0.09 mmol, 10 mol %), and Selectfluor (67 mg, 0.19 mmol, 
20 mol %) were added and stirred for 12 hours before filtering the salts. After rinsing the salts 
with CH3CN (6 mL) the filtrate was dried over sodium sulfate and concentrated to yield a dark 
orange oil. TLC and 1H NMR analysis exhibited no product formation. 
 
Scheme 4.7: Amidation of 3,4-dimethoxybenzoic acid19 
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In a 20 mL oven dried round bottom flask 3,4-dimethoxybenzoic acid (0.5 g, 2.7 mmol, 1 eq) 
was dissolved in THF (13 mL) with a magnetic stir bar. To this was added thionyl chloride (0.3 
mL, 0.5 g, 4.1 mmol, 1.5 eq) in dropwise fashion. After stirring for 10 minutes the reaction flask 
was heated in an oil bath (50 °C, 1 hr) before cooling to room temperature and then placing in an 
ice bath for 10 minutes. Ice-cold ammonium hydroxide (30%, 3.0 mL, 2.6 g, 0.08 mmol, 0.03 
eq) was slowly injected into the chilled reaction flask, exhibiting large volumes of white smoke. 
After stirring for 5 minutes the solution (and a white precipitate) were extracted with CHCl3 (3 x 
35 mL). The combined organic layers were dried over sodium sulfate and concentrated. The 
resulting solid was soaked with hexane and collected by vacuum filtration. The product was an 
off-white solid (250 mg, 50% yield). A significant portion of the reaction mixture was lost to the 
benchtop during transfer and likely contributed to a lower-than-expected yield 
 
Scheme 4.8: Palladium catalyzed dehydration of 3,4-dimethoxybenzamide19 
In an oven dried 50 mL round bottom flask 3,4-dimethoxybenamide (0.10 g, 0.55 mmol, 1 eq), 
palladium acetate (12 mg, 0.06 mmol, 10 mol %), Selectfluor (39 mg, 0.11 mmol, 20 mol %), 
and K2CO3 (150 mg, 1.1 mmol, 2 eq) were combined in CH3CN (18 mL) with a magnetic stir 
bar. The solution was stirred for 9 hours before the salts were filtered, and the filtrate dried over 
sodium sulfate before concentration under reduced atmosphere. The resulting solid was purified 
by silica gel column (150 mL, 5% EtOAc: Hex), yielding an off-white solid (6.5 mg, 7% yield).  
 
Scheme 4.9: Doped Solvent Dehydration of 3,4-dimethoxybenzamide 
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In an oven dried 25 mL round bottom flask, K2CO3 (0.15 g, 1.1 mmol, 2 eq) and CH3CN (5.0 
mL) were stirred (2 hours) before filtering the solids from the solution. The filtrate was returned 
to the solid-free reaction flask before adding palladium acetate (12 mg, 0.06 mmol, 10 mol %), 
and Selectfluor (39 mg, 0.11 mmol, 20 mol %). After stirring (5 minutes) 3,4-
dimethoxybenzamide (0.1 g, 0.55 mmol, 1 eq) was added to the reaction flask. The dark orange 
solution was stirred for 9 hours before drying over sodium sulfate and concentration under 
reduced atmosphere.  The dark orange oil was purified by silica gel column (150 mL, 100% 
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APPENDIX A: SUPPORTING INFORMATION 
Supporting information for Development and Utilization of a Palladium-Catalyzed Dehydration 
of Primary Amides to Form Nitriles, presented as published in the Journal of Organic Chemistry. 
Mohammed H. Al-Huniti, José Rivera-Chávez, Katsuya L. Colón, Jarrod L. Stanley, Joanna E. 
Burdette, Cedric J. Pearce, Nicholas H. Oberlies, and Mitchell P. Croatt  
General Synthetic Information 
All anhydrous reactions were performed in oven dried glassware under a nitrogen atmosphere. 
Unless otherwise noted, all solvents and reagents were obtained from commercial sources and 
used without further purification. Chromatographic purification was performed using silica gel 
(60 Å, 32-63 µm). NMR spectra were recorded in CDCl3, acetone-d6, or DMSO-d6 using a JEOL 
ECA 400 spectrometer (400 MHz for 1H, 100 MHz for 13C, and 376.5 MHz for 19F), and JEOL 
ECA spectrometer (500 MHz for 1H, 125 MHz for 13C, and 470 MHz for 19F). Coupling 
constants, J, are reported in hertz (Hz) and multiplicities are listed as singlet (s), doublet (d), 
triplet (t), quartet (q), quintet (quint), doublet of doublets (dd), triplet of triplets (tt), multiplet 
(m), etc. High Resolution Mass Spectra were acquired on a Thermo Fisher Scientific LTQ 
Orbitrap XL MS system.  
General Procedure for the Synthesis of Amides 9a-9v  
To an oven dried round-bottom flask, benzoic acid (1000 mg, 8.18 mmol) was dissolved in dry 
THF (25.0 mL) and then thionyl chloride (0.89 mL, 12.3 mmol) was added. The reaction mixture 
was heated to 50 °C for 1 hr and then allowed to cool to room temperature. The THF solution 
was cooled to 0 °C and then carefully poured into an icecooled ammonium hydroxide solution 
(37%, 6.0 mL) while stirring. After 5 min, the mixture was extracted with CHCl3 (3 x 75.0 mL). 
The organic extract was dried and evaporated.  The resultant solid was then soaked with hexane 
and filtered to obtain the desired amide in a pure form. 
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1H and 13C NMR spectra for compounds 9a–9v are consistent with literature reports.  
General Procedure for the Synthesis of Nitriles 10a-10v 
To an oven dried microwave vial containing 4-methoxybenzamide (151.1 mg, 1.0 mmol) in 
acetonitrile (0.1 M), palladium acetate (22.4 mg, 0.1 mmol) and Selectfluor (70.8 mg, 0.2 mmol) 
were added. The reaction mixture was stirred at room temperature for 18 hr and then purified by 
column chromatography (gradient elution from pure hexane to 10% EtOAc in hexane) without 
the removal of solvent.   Product was isolated as a white solid (126 mg, 96% yield).  
1H and 13C NMR spectra for compounds 10a – 10v are consistent with literature reports 1H NMR 
and 13C NMR. 
 
Figure A1: Spectroscopic Data for 4-Methoxybenzamide 9a and Corresponding Nitrile 10a         




Figure A2: Spectroscopic Data for 4-Methoxybenzamide 9a and Corresponding Nitrile 10a         









Figure A4: Spectroscopic Data for 4-Methoxybenzamide 9a and Corresponding Nitrile 10a (4 of 
4) 
 
Figure A5: Spectroscopic Data for Benzamide 9b and Corresponding Nitrile 10b (1 of 3) 
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Figure A7: Spectroscopic Data for Benzamide 9b and Corresponding Nitrile 10b (3 of 3)   
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Figure A10: Spectroscopic Data for 4-Chlorobenzamide 9c and Corresponding Nitrile 10c (3 of 
3) 
 
Figure A11: Spectroscopic Data for 4-(trifluoromethyl)benzamide 9d and Corresponding Nitrile 




Figure A12: Spectroscopic Data for 4-(trifluoromethyl)benzamide 9d and Corresponding Nitrile 




Figure A13: Spectroscopic Data for 4-(trifluoromethyl)benzamide 9d and Corresponding Nitrile 




Figure A14: Spectroscopic Data for 4-(trifluoromethyl)benzamide 9d and Corresponding Nitrile 
10d (4 of 4) 
 
Figure A15: Spectroscopic Data for 3,5-dimethylbenzamide 9e and Corresponding Nitrile 10e   
(1 of 3) 
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Figure A16: Spectroscopic Data for 3,5-dimethylbenzamide 9e and Corresponding Nitrile 10e   




Figure A17: Spectroscopic Data for 3,5-dimethylbenzamide 9e and Corresponding Nitrile 10e   




Figure A18: Spectroscopic Data for 2,4-Dichlorobenzamide 9f and Corresponding Nitrile 10f    




Figure A19: Spectroscopic Data for 2,4-Dichlorobenzamide 9f and Corresponding Nitrile 10f   




Figure A20: Spectroscopic Data for 2,4-Dichlorobenzamide 9f and Corresponding Nitrile 10f   
(3 of 3) 
 
Figure A21: Spectroscopic Data for 3,4-Dimethoxybenzamide 9g and Corresponding Nitrile 10g 




Figure A22: Spectroscopic Data for 3,4-Dimethoxybenzamide 9g and Corresponding Nitrile 10g 




Figure A23: Spectroscopic Data for 3,4-Dimethoxybenzamide 9g and Corresponding Nitrile 10g 




Figure A24: Spectroscopic Data for (E)-Cinnamamide 9h and Corresponding Nitrile 10h (1 of 4) 
 
 








Figure A27: Spectroscopic Data for (E)-Cinnamamide 9h and Corresponding Nitrile 10h (4 of 4) 
 
 
Figure A28: Spectroscopic Data for (E)-3-(3-trifluoromethyl)phenyl)acrylamide 9i and 




Figure A29: Spectroscopic Data for (E)-3-(3-trifluoromethyl)phenyl)acrylamide 9i and 




Figure A30: Spectroscopic Data for (E)-3-(3-trifluoromethyl)phenyl)acrylamide 9i and 




Figure A31: Spectroscopic Data for (E)-3-(4-methoxyphenyl)acrylamide 9j and Corresponding 




Figure A32: Spectroscopic Data for (E)-3-(4-methoxyphenyl)acrylamide 9j and Corresponding 




Figure A33: Spectroscopic Data for (E)-3-(4-methoxyphenyl)acrylamide 9j and Corresponding 




Figure A34: Spectroscopic Data for (E)-3-(furan-2-yl)acrylamide 9k and Corresponding Nitrile 




Figure A35: Spectroscopic Data for (E)-3-(furan-2-yl)acrylamide 9k and Corresponding Nitrile 




Figure A36: Spectroscopic Data for (E)-3-(furan-2-yl)acrylamide 9k and Corresponding Nitrile 
10k (3 of 3) 
 
 
Figure A37: Spectroscopic Data for (2E,4E)-5-phenylpenta-2,4-dienamide 9l and Corresponding 
Nitrile 10l (1 of 4) 
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Figure A38: Spectroscopic Data for (2E,4E)-5-phenylpenta-2,4-dienamide 9l and Corresponding 




Figure A39: Spectroscopic Data for (2E,4E)-5-phenylpenta-2,4-dienamide 9l and Corresponding 




Figure A40: Spectroscopic Data for (2E,4E)-5-phenylpenta-2,4-dienamide 9l and Corresponding 
Nitrile 10l (4 of 4) 
 
 
Figure A41: Spectroscopic Data for 1-methyl-1H-pyrrole-2-carboxamide 9m and Corresponding 




Figure A42: Spectroscopic Data for 1-methyl-1H-pyrrole-2-carboxamide 9m and Corresponding 




Figure A43: Spectroscopic Data for 1-methyl-1H-pyrrole-2-carboxamide 9m and Corresponding 




Figure A44: Spectroscopic Data for 2,2-diphenylacetamide 9n and Corresponding Nitrile 10n   




Figure A45: Spectroscopic Data for 2,2-diphenylacetamide 9n and Corresponding Nitrile 10n    




Figure A46: Spectroscopic Data for 2,2-diphenylacetamide 9n and Corresponding Nitrile 10n    





Figure A47: Spectroscopic Data for 2-(4-nitrophenyl)acetamide 9o and Corresponding Nitrile 




Figure A48: Spectroscopic Data for 2-(4-nitrophenyl)acetamide 9o and Corresponding Nitrile 




Figure A49: Spectroscopic Data for 2-(4-nitrophenyl)acetamide 9o and Corresponding Nitrile 
10o (3 of 3) 
 
Figure A50: Spectroscopic Data for 4-phenylbutanamide 9p and Corresponding Nitrile 10p      




Figure A51: Spectroscopic Data for 4-phenylbutanamide 9p and Corresponding Nitrile 10p      




Figure A52: Spectroscopic Data for 4-phenylbutanamide 9p and Corresponding Nitrile 10p      




Figure A53: Spectroscopic Data for Cyclohexanecarboxamide 9q and Corresponding Nitrile 10q 




Figure A54: Spectroscopic Data for Cyclohexanecarboxamide 9q and Corresponding Nitrile 10q 




Figure A55: Spectroscopic Data for Cyclohexanecarboxamide 9q and Corresponding Nitrile 10q 
(3 of 3) 
 
 












Figure A59: Spectroscopic Data for Adamantane-1-carboxamide 9s and Corresponding Nitrile 




Figure A60: Spectroscopic Data for Adamantane-1-carboxamide 9s and Corresponding Nitrile 




Figure A61: Spectroscopic Data for Adamantane-1-carboxamide 9s and Corresponding Nitrile 




Figure A62: Spectroscopic Data for 1-(4-methoxyphenyl)cyclopropane-1-carboxamide 9t and 




Figure A63: Spectroscopic Data for 1-(4-methoxyphenyl)cyclopropane-1-carboxamide 9t and 




Figure A64: Spectroscopic Data for 1-(4-methoxyphenyl)cyclopropane-1-carboxamide 9t and 




Figure A65: Spectroscopic Data for 1-(4-chlorophenyl)cyclopropane-1-carboxamide 9u and 




Figure A66: Spectroscopic Data for 1-(4-chlorophenyl)cyclopropane-1-carboxamide 9u and 




Figure A67: Spectroscopic Data for 1-(4-chlorophenyl)cyclopropane-1-carboxamide 9u and 




Figure A68: Spectroscopic Data for 2,2-dimethyl-1-(p-tolyl)cyclopropane-1-carboxamide 9v 




Figure A69: Spectroscopic Data for 2,2-dimethyl-1-(p-tolyl)cyclopropane-1-carboxamide 9v 




Figure A70: Spectroscopic Data for 2,2-dimethyl-1-(p-tolyl)cyclopropane-1-carboxamide 9v 




Figure A71: Stacked 1H NMR Spectra for Reaction of 9a 
 
 
Figure A72: Stacked 19F Spectra for Reaction of 9a 
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General Experimental Procedures with Alamethicin F50 
The circular dichroism experiments were conducted in an Olis, DSM 17 CD spectrometer (Olis, 
Inc.) at a concentration of 100 ppm in MeCN at 25 °C. NMR experiments were conducted in 
DMSO-d6. NMR instrumentation was a JEOL ECA-500 NMR spectrometer operating at 500 
MHz for 1H, and 125 MHz for 13C, or an Agilent 700 MHz NMR spectrometer equipped with a 
cryoprobe, operating at 700 MHz for -1H and 175 MHz for 13C. HRESIMS data was obtained 
using a Thermo QExactive Plus mass spectrometer (ThermoFisher Scientific) paired with an 
electrospray ionization source. The higher energy collisional dissociation (HCD) used a 
normalized energy of 35 for all the compounds to obtain MS/MS data. The UPLC separations 
were performed using a Waters Acquity system (Waters Corp.) using a BEH C18 column (50 
mm × 2.1 mm, internal diameter, 1.7 µm) equilibrated at 40 °C and a flow rate set at 0.3 
mL/min. The mobile phase consisted of a linear MeCN-H2O (acidified with 0.1% formic acid) 
gradient starting at 15% MeCN to 100% MeCN over 8 min. The mobile phase was held for 
another 1.5 min at 100% MeCN before returning to the starting conditions. The HPLC 
separations were performed using a Varian ProStar HPLC system connected to a ProStar 335 
photodiode array detector (PDA) with UV detection set at 195 and 210 nm. Preparative HPLC 
purifications of isolated compounds were performed on an Atlantis T3 5 µm particle size C18 
column (19 x 250 mm) at a flow rate of 17.0 mL/min, or a Phenomenex Synergi 4 µm particle 
size C12 column (21 x 250 mm) at a flow rate of 20.0 mL/min. Flash column chromatography 
was carried out with a Teledyne ISCO Combiflash Rf connected to ELSD S64 and PDA 
detectors, with the latter having UV detection set at 200-400 nm, all according to established 
protocols. All solvents were obtained from Fisher Scientific and used without further 
purification. 
Fermentation, Extraction, and Isolation of Alamethicin F50 
Fungal strain MSX70741 (Trichoderma arundinaceum) was isolated, identified, and grown as 
detailed previously. Approximately 130 mg of alamethacin F50 (1) was isolated from four scale-
up cultures of MSX70741 as explained in detail recently. 
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Analysis of Alamethicin F50 Dehydration 
The reaction analysis was carried out using UPLC/HRESIMS. The higher energy collisional 
dissociation (HCD) used a normalized energy of 35 for all the compounds to obtain MS/MS data. 
The UPLC separations were performed using an Acquity BEH C18 column (50 mm × 2.1 mm, 
internal diameter, 1.7 µm) equilibrated at 40 °C and a flow rate set at 0.3 mL/min. The mobile 
phase consisted of a linear MeCN-H2O (acidified with 0.1% formic acid) gradient starting at 
40% MeCN to 100% MeCN over 3.7 min. The mobile phase was held for another 0.7 min at 
100% MeCN before returning to the starting conditions. The area under the curve for each 
product was extracted from the base peak chromatogram using Thermo Xcalibur Qual Browser 




Figure A73: UPLC-HRESIMS analysis of the crude reaction of alamethicin F50 (1), Pd(OAc)2 
(5 mol %) and SelectFluor (1.0 equiv.) at room temperature, after 90 min. In 
Black the base peak chromatogram. In red the extracted ion chromatogram for 
alamethicin F50 (1), in green the extracted ion chromatogram for 
mononitrilealamethicin F50 derivatives (6-8), in blue the extracted ion 
chromatogram for dinitrilealamethicin F50 derivatives (3-5) and in yellow the 




Figure A74: Overlapped UPLC-HRESIMS analysis of the crude reaction of alamethicin F50 (1), 
Pd(OAc)2 (5 mol %) and SelectFluor (1.0 equiv.) at room temperature, after 90 min. In black, the 
base peak chromatogram. The extracted ion chromatograms detailed above are overlaid with 
each other. In red, the extracted ion chromatogram for alamethicin F50 (1). In green, the 
extracted chromatogram for mononitrilealamethicin F50 derivatives (6-8). In blue, the extracted 
chromatogram for dinitrile alamethicin F50 derivatives (3-5). In yellow, the extracted 
chromatogram for trinitrilealamethicin F50 derivative (2). 
 
The conditions for dehydration of alatheicin F50 were examined with analysis by UPLC every 
20 minutes. Figures A85-A87 show the formation of different analogues over time under the 
standard conditions (Figure A85), using a mixture of acetonitrile and dioxane (Figure A86), and 
in the absence of SelectFluor (Figure A87). 
 
Figure A75: Analysis of the reaction between 1 (0.5 mmol), Pd(OAc)2 (5 mol %) and 
SelectFluor (1.0 eq) in MeCN (1 mL) at room temperature. The reaction was monitored via 




Figure A76: . Analysis of the reaction between 1 (0.5 mmol), Pd(OAc)2 (5 mol %) and 
SelectFluor (1.0 eq) in MeCN-Dioxane 1:1 (1.0 mL). The reaction was monitored 
via UPLC-HRESIMS at intervals of 20 min 
 
 
Figure A77: Analysis of the reaction between 1 (0.5 mmol) and Pd(OAc)2 (5 mol %) in MeCN 
(1.0 mL) at room temperature. The reaction was monitored via UPLC-HRESIMS 
at intervals of 20 min. 
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Synthesis, Isolation and Characterization of Compounds 1-8 
To a vial containing alamethicin F50 (10.0 mg, 0.005 mmol) in acetonitrile (1.0 M), were added 
palladium acetate (0.11 mg, 0.0005 mmol) and Selectfluor (1.8 mg, 0.005 mmol). The reaction 
mixture was stirred at room temperature for 90 min. The reaction mixture was directly subjected 
to preparative HPLC purification on an Atlantis T3 column, using a gradient system initiated 
with 80:20 MeCN-H2O (0.1% formic acid) to 100 % CH3CN over 30 min at a flow rate of 17.0 
mL/min to generate eight fractions (FI-VIII). HRESIMS/MS of each fraction, using the method 
described in general experimental procedures, allowed the identification and characterization of 
each derivative, as shown in Figures 7-14 
 
Figure A78: . Structures of alamethicin F50 (1, Ac-Aib1 -Pro2 -Aib3 -Ala4 -Aib5 -Ala6 -Gln7 -




Figure A79: A) Full scan HRESIMS spectrum of compound 1. B) Expansion of the [M + H]+ 
ion for alamethicin F50 (1) at m/z 1963.13 (∆ = -3.8 ppm). The peak at 774.44 
indicates the fragment y7 + (-Pro14-Val15-Aib16- Aib17-Gln18-Gln19-Pheol20). The 
peak at 1189.68 indicates the indicates the fragment b13+ (Ac-Aib1 -Pro2 -Aib3 -




Figure A80: A) Full scan HRESIMS spectrum of compound 2 B) Expansion of the [M + H]+ 
ion for compound 7 at m/z 1909.10 (∆ = -3.0 ppm). The peak at 738.42 indicates the dehydration 
of Gln18 and Gln19 in fragment y7 + . The peak at 1171.67 indicates the dehydration of Gln7 in 
fragment b13+ . 
 
Figure A81: A) Full scan HRESIMS spectrum of compound 3. B) Expansion of the [M + H]+ 
ion for compound 3 at m/z 1928.11 (∆ = -3.3 ppm). The peak at 738.42 indicates the dehydration 
of Gln18 and Gln19 in fragment y7 + . 
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Figure A82: A) Full scan HRESIMS spectrum of compound 4. B) Expansion of the [M + H]+ 
ion for compound 4 at m/z 1928.11 (∆ = -3.3 ppm). C) MS2 of ion 964.6 indicating the losses 
Pheol20, CN-Gln19 and Gln18 and positioning the dehydrated Gln residue in the y7 + fragment of 
the molecule. The peak at 1171.67 indicates the dehydration of Gln7 in fragment b13+ 
 
Figure A83: A) Full scan HRESIMS spectrum of compound 5. B) Expansion of the [M + H]+ 
ion for compound 5 at m/z 1928.11 (∆ = -3.3 ppm). C) MS2 of ion 756.4 indicating the losses 
Pheol20, Gln19 and CN-Gln18 and positioning the dehydrated Gln residue in the fragment y7 + of 
the molecule. The peak at 1171.67 indicates the dehydration of Gln7 in fragment b13+ 
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Figure A84: A) Full scan HRESIMS spectrum of compound 6. B) Expansion of the [M + H]+ 
ion for compound 6 at m/z 1945.12 (∆ = -3.6 ppm). C) MS2 of the ion 756.4 
indicating the losses Pheol20, CN-Gln19 and Gln18 and positioning the dehydrated 
Gln residue in the fragment y7 + of the molecule. 
  
Figure A85: A) Full scan HRESIMS spectrum of compound 7. B) Expansion of the [M + H]+ 
ion for compound 7 at m/z 1945.12 (∆ = -3.6 ppm). C) MS2 of the ion 756.4 
indicating the losses Pheol20, Gln19 and CN-Gln18 and positioning the dehydrated 




Figure A86: Full scan HRESIMS spectrum of compound 8. B) Expansion of the [M + H]+ ion 
for compound 8 at m/z 1945.12 (∆ = -3.6 ppm). The peak at 1171.67 indicates the 
dehydration of Gln7 in fragment b13+ . 
 
 





Figure A88: Expansion of the 1H NMR amide region of compounds 1 (bottom) and 2 (top), 
recorded at 700 MHz in DMSO-d6 
 
 




Figure A90: Expansion of the 13C NMR of compounds 1 (bottom) and 2 (top), recorded at 175 
MHz in DMSO-d6, showing the carbons attributed to the aromatic moiety in 1, the 
aromatic ring and nitrile carbons (120 – 121 ppm) in 2. 
 
 
Figure A91: Full spectra overlay of far UV/CD spectra for alamethicin F50 (1) and its 




Figure A92: . Zoomed in image of far UV/CD spectra for alamethicin F50 (1) and its dehydrated 
analogues (2-8). 
Cytotoxicity Assay 
Human melanoma cancer cells MDA-MB-435, human breast cancer cells MDA-MB-231, and 
human ovarian cancer cells OVCAR3 were purchased from the American Type Culture 
Collection (Manassas, VA, USA). The cell lines were propagated at 37 °C in 5% CO2 in RPMI 
1640 medium, supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and 
streptomycin (100 µg/mL). Cells in log phase of growth were harvested by trypsinization 
followed by two washes to remove all traces of enzyme. A total of 5,000 cells were seeded per 
well of a 96-well clear, flat-bottom plate (Microtest 96, Falcon) and incubated overnight (37 °C 
in 5% CO2). Samples dissolved in DMSO were then diluted and added to the appropriate wells 
(several concentrations; total volume: 100µL; DMSO: 0.5%). The cells were incubated in the 
presence of test substance for 72 h at 37 °C and evaluated for viability with a commercial 
absorbance assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega Corp, 
Madison) that measured viable cells. IC50 values were determined as the concentration required 
to reduce cellular proliferation by 50% relative to the untreated controls following 72 h of 
continuous exposure. Paclitaxel (taxol) was used as a positive control. 
